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ABSTRACT 
A simple, accurate and precise HPTLC method has been developed and validated for the 
estimation of nevirapine from bulk drug and tablet formulations. The separation was achieved on 
TLC plates using appropriate solvent system. The spots so developed were densometrically 
scanned at 283 nm. The linearity of the method was found to be within the concentration range 
of 2.50µg/ml to 62.50µg/ml. The validation parameters, tested in accordance with the 
requirements of ICH guidelines, prove the suitability of this method. The method was 
successfully applied for determination of drug in tablets, wherein no interference from tablet 
excipients was observed, indicating the specificity of the developed method. Thus the proposed 
method can be used successfully for routine analysis of nevirapine from capsule and tablet 
formulations. 
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INTRODUCTION 
Nevirapine (Fig.1), 11-cyclopropyl-4-methyl-5, 11-dihydro-6H-dipyrido [3, 2-b: 2’, 3’-
e][1,4] diazepin-6-one is a reverse transcriptase (RT) inhibitor of human immunodeficiency virus 
type 1 (HIV-1)1,2. Nevirapine inhibits replication of HIV-1 by interfering with viral RNA-
directed DNA polymerase (reverse transcriptase). It binds directly to herodimeric HIV-1 reverse 
transcriptase and exerts a virustatic effect by acting as a specific, noncompetitive HIV-1 reverse 
transcriptase inhibitor; it appears to inhibit viral RNA- and DNA-dependent DNA polymerase 
activities by disrupting the catalytic site of the enzyme 3.  
Literature survey reveals that there are analytical methods available for determination of 
nevirapine from biological matrices 4-14, bulk drug and dosage forms 15-17, and analytical methods 
for determination of nevirapine with combination of other antiviral drugs 18-50 Literature survey 
further revealed that there were very few reported HPTLC method for the analysis of nevirapine. 
Thus, an appropriate analytical procedure for the quantitative determination of nevirapine from 
bulk drugs is of considerable importance.  
Keeping this objective in mind an attempt has been made to develop and validate HPTLC 
method for the analysis of nevirapine which would be highly sensitive, having good resolution 
and reproducible. Various validation aspects of the analysis, accuracy, precision, recovery and 
the limits of detection and quantification etc., have been measured. 
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EXPERIMENTAL 
Chemicals and Reagents 
The working standard of nevirapine was procured from Cipla Ltd., India. HPLC grade 
ethyl acetate and methanol was purchased from Merck (Darmstadt, Germany). Deionised and 
ultra pure water used in all experiments was obtained from Milli-Q System (Millipore). Glacial 
acetic acid of AR (Analytical Reagent) grade was procured form S. D. Fine Chemicals (India).  
Equipment 
The HPTLC system employed in the method development and validation was Camag 
Linomat V applicator (Muttenz, Switzerland), a Camag twin trough chamber of appropriate size, 
Camag TLC scanner III, Wincats (version 1.2.2) software as data integrator and a Hamilton 
syringe (Switzerland) of 100µl capacity.   
Preparation of Standard Solution 
A stock solution of nevirapine (1mg/ml) was prepared in methanol. Standard solution 
was prepared by dilution of the stock solution with methanol to give solution in of 100µg/ml. 
Further dilutions were made with methanol to give solution in concentration range of 2.50µg/ml 
to 62.50µg/ml. 
HPTLC 
Prewashing of Plates 
HPTLC was performed on 10 cm x 20 cm precoated silica gel GF254 pre-coated HPTLC 
plates from E.Merck (Darmstadt, Germany). The adsorbent has a very large surface area; it may 
absorb air and other impurities from atmosphere, particularly volatile impurities, after the pack 
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has been opened. The non volatile impurities adsorbed by layer can lead to irregular baseline in 
scanning densitometry. To avoid possible interference from such impurities in quantitative 
analysis, plates were prewashed with methanol, dried and activated for 30 min at 1100C, with the 
plates being placed between two sheets of glass to prevent deformation of the aluminium during 
heating. 
Procedure 
A methanolic solution of nevirapine (1mg/ml) was prepared. This solution was further 
diluted with methanol to yield a solution containing 100 µg/ml. Different concentration of 
nevirapine in concentration range of 2.50µg/ml to 62.50µg/ml were applied on plates as 6 mm 
bands, 6 mm apart and 1 cm from edge of the plate, by means of Camag Linomat V automatic 
sample applicator fitted with 100 µl Hamilton syringe. A methanol blank was applied to parallel 
track. After drying of bands, the plate was placed in one of the troughs of Camag twin trough 
glass chamber. The mobile phase, ethyl acetate: glacial acetic acid (10:0.1 %v/v) was poured into 
the second trough and the plates were left to equilibrate in the chamber for 10 min at 25 + 2 0C. 
The plate was then moved to the second trough containing the mobile phase and developed to a 
distance 90 mm. After development, the plate was removed from the chamber, dried in current of 
hot air, and scanned at 283 nm, using a deuterium lamp, by means of Camag TLC scanner III 
densitometer. The representative densitogram obtained by HPTLC of nevirapine at various 
concentrations are shown in Fig.3. This method was followed for all quantitative analysis. 
Wincats software (version 1.2.2) was used for data acquisition and processing of the plate. The 
scanning speed was 20 mm s-1 , the offset was 10 %, and the sensitivity (SPAN) was optimized 
to 20 min. Peak height and peak area were integrated for the entire track. Calibration curve was 
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established by plotting the obtained peak area on ordinate against corresponding concentration 
on abscissa. The reproducibility of this method was ascertained by repeating the experiment six 
times.  
Method Validation 
 The method was validated for specificity, accuracy, precision by use of calibration 
standards of nevirapine. Limit of detection and limit of quantitation were determined by the 
visual method, by spotting different concentration of nevirapine. The lowest concentration that 
could be detected for three replicate spots was regarded as the limit of detection. The lowest 
concentration for which the RSD [%] of six replicate spots was less than 5 % was regarded as the 
limit of quantitation. LOD was calculated using formula LOD=3.3xσ/S, where σ is residual 
standard deviation of regression line and S is the slope of corresponding line. Accuracy was 
determined by measurement of the recovery of nevirapine standard added at three different 
levels, each being analyzed as described for the assay. Intraday and interday precision was 
determined by applying 7.50µg/ml, 25.00µg/ml and 62.50µg/ml standard nevirapine. After 
development and densitometric scanning of the plates the peak-area response was measured and 
precision was calculated as RSD [%]. The method was validated as per ICH guidelines.51    
Application of the validated method 
To determine the content of the drug in solid dosage form, 20 tablets of nevirapine (200 
mg) were accurately weighed, their average weight was calculated. Powder equivalent to 200 mg 
of the drug was dissolved in 100 ml methanol in a volumetric flask and sonicated for 20 min. 
(Solution A ~ 2000 µg/ml). Further dilutions were made with mobile phase as follows: 1 ml of 
Solution A was diluted to 100ml in a volumetric flask (Solution B ~ 20 µg/ml). 1ml of Solution 
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B was diluted to 10ml in a volumetric flask (Solution C ~ 2 µg/ml). This Solution C was spotted 
(40µl) on to the HPTLC plate. The average area of 6 such spots was taken for calculation. 
Concentration of nevirapine was calculated from the standard graph, which was plotted using the 
area of known concentration (2.50-62.50µg/ml) of nevirapine standard. The results are 
summarized in Table 1.  
 
 
Label Claim 200 mg 
Amount found ±SD (n=6)  201.11 ± 0.522 mg 
% Label Claim 100.56 % 
% RSD 0.259 
                              n= no. of repetitions 
 
Table 1 Assay of Nevirapine in Tablet 
       
Linearity and range Nevirapine  
Range (µg/ml) 2.50 - 62.50 
r2 0.9959 
Slope  396.88 
 
Table  2 Linearity and Range 
 
 
 
 
 
JPRHC                 
 Research Article 
	
 2009  Page 203 
 
 
 
 
Precision  
         % Recovery   
Actual Concentration 
             (µg/ml) 
Measured Concentration 
       (µg/ml) ± S.D.; % R.S.D. 
 Intra-day Inter-day Intra-day Inter-day 
7.50  
7.56 ± 0.22; 
2.96 
7.49 ± 0.20; 
2.72 
100.76 99.84 
25.00 
24.65 ± 0.519;   
2.06 
24.84 ± 0.50;   
2.01 
98.61 99.38 
62.50 
62.54 ± 0.77; 
1.23 
62.38 ± 0.70; 
1.12 
100.07 99.81  
 
Table 3 Precision and Recovery data 
 
 
Fig.1Chemical Structure of Nevirapine 
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Fig. 2 A typical Absorption Spectrum of Nevirapine Scanned at 200-400 nm 
 
Fig. 3 Representative Chromatogram of Standard 25µg/ml Nevirapine at 283 nm 
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Fig. 4 Representative Chromatogram of Formulation of Nevirapine at 283 nm 
 
 
 
RESULTS AND DISCUSSION 
The solvent chosen for HPTLC must take into account the chemical nature and polarity 
of the drug molecule. Nevirapine is practically insoluble in water, soluble in dichloromethane, 
dimethylsulphoxide and dimethylformamide, slightly soluble in methanol. Calibrator solutions 
were prepared in methanol. Solubility increases at pH <3. Initially acetonitrile: water (1:1) was 
used as the solvent system, but it was observed that the spot did not travel at all and RF value 
was found to be negligible. Solvent system comprising of acetonitrile: water (2:1), methanol: 
water (2:1) were tried but again RF value was found to be negligible. Thus after much trials 
solvent system comprising of ethyl acetate gave good separation and there was no interference 
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around the drug RF. Slight tailing was observed which was removed when 0.1% glacial acetic 
acid was added in the solvent system Thus after much experiment, the optimized system was 
developed which consisted of ethyl acetate: glacial acetic acid (10:0.1 %v/v). The optimized 
system gave a good separation and resolution of nevirapine.  
The plate material employed was silica gel 60 GF254. Scanning of nevirapine on HPTLC 
plate showed UV max at 283 nm (Fig.2) hence quantitation was carried out at 283 nm using 
Camag TLC scanner III. 
The method developed was validated for limit of detection (LOD) and limit of 
quantitation (LOQ) in order to determine and ensure sensitivity of the developed method. The 
limit of detection (LOD) and limit of quantitation (LOQ) was found to be 0.84 and 2.5µg per 
spot respectively. The method was found to be linear over the range 2.50 - 62.50µg per spot with 
coefficient of regression 0.9959. (Table 2) Intra-day and inter-day precision studies showed a % 
RSD was less than 5.00%, indicating the method was precise. The accuracy values obtained, in 
the range 98.61 – 100.76 % for drug are indicative of excellent accuracy and recovery. There 
was no evidence of peaks or any other interfering co eluting peaks at the RF of standard (0.44). 
This indicates the method is specific. Stability studies were carried out for standard. It was found 
to be stable in sample solution, prior to development and after development. 
 
The developed method was then validated and successfully applied for quantitation of 
nevirapine from the formulation. To ensure accuracy of the method, recovery studies were 
performed by standard addition method at 80%, 100% and 120% level, to the pre-analyzed 
samples and the subsequent solutions were re-analyzed. At each level, three determinations were 
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performed and the results obtained are shown in Table 3. The results of recovery studies were 
within the specified limits of ICH guidelines. Lower values of %RSD reflect the accuracy of the 
method. Precision, expressed in terms of %RSD was determined in terms of intra-day and inter-
day precisions, analyzing the drug at three different concentrations, determining each 
concentration thrice. The sample solutions were analyzed using the method for 3 consecutive 
days, repeating the process twice a day at different period. The results obtained are summarized 
in Table 3 and reflect high degree of precision. Two different analysts performed assay on 
marketed tablets of the drug, in similar operational and environmental conditions, using the 
developed method to determine its ruggedness. 
 
` The optimized solvent system yielded a symmetrical peak for the drug with RF 0.44 
(Fig.3). A typical absorbance spectrum of the drug is shown in Fig.2. The peak of the drug from 
tablets (Fig.4) was identified by comparing the RF and also comparing its absorbance spectrum 
with that obtained with the standard drug. 
CONCLUSION 
The developed and validated HPTLC method reported here is rapid, simple, accurate, 
sensitive and specific. The method was also successfully used for quantitative estimation and 
analysis of nevirapine from formulation. Thus the reported method is of considerable importance 
and has great industrial applicability for quality control and analysis of nevirapine from bulk 
drug and formulations. 
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